Monthly obstetrics and gynecology bulletin — November 12, 2026
This issue covers what was published, presented, or released between October 15 and November 12, 2026. It was a congress-driven period: ESMO in Madrid delivered three phase 3 trials in endometrial cancer (two of them published simultaneously in The Lancet), The Menopause Society and the American Heart Association contributed large observational datasets on hormone therapy and testosterone, and ACOG issued two guidance documents (GLP-1 receptor agonists in pregnancy and lactation; menopause-related vasomotor, sleep, and mood symptoms). Ten items in total.
Obstetrics and maternal-fetal medicine
1. Early metformin in gestational diabetes: less insulin, but still no change in the primary outcome (EMERGE)
[Publication] [Ireland]
Secondary analysis of the EMERGE trial (double-masked, placebo-controlled, two Irish hospitals, 535 pregnancies randomized, 526 analyzed) published in JAMA Network Open on November 3, 2026, and funded by the Health Research Board of Ireland. Using generalized pairwise comparisons, metformin started at diagnosis versus placebo showed an overall win ratio of 1.46 (95% CI, 1.13-1.89; P = .004), driven by less insulin initiation (win ratio 1.68; 95% CI, 1.19-2.38), with no difference in fasting hyperglycemia at week 32 (win ratio 0.99) and a favorable signal at week 38 that was significant only in the nonprioritized analysis (2.38; 95% CI, 1.29-4.38).
Why it matters: the authors state that the analysis was not prespecified and that the hierarchy was defined after trial completion, so it does not overturn the neutral original primary outcome; it does suggest that, where insulin is expensive or hard to manage, early metformin may reduce its need.
Sources
- [Article] Aguilar Macías DA, Alvarez-Iglesias A, Ferguson JM, et al. «Early Metformin Initiation and Glycemic Outcomes in Gestational Diabetes: A Secondary Analysis of a Randomized Clinical Trial». JAMA Netw Open. 2026;9(11):e2635700. DOI: 10.1001/jamanetworkopen.2026.35700. Open access (CC BY-NC-ND). https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2856230
2. Gestational weight gain and severe maternal morbidity in one million births
[Publication] [Canada]
Retrospective population-based cohort from Ontario (1,035,927 singleton pregnancies with hospital delivery, April 2012 to March 2022) published in JAMA Network Open on October 22, 2026. Severe maternal morbidity occurred in 14.59 per 1,000 births. Compared with adequate gain by Institute of Medicine criteria, excessive gain was associated with higher risk across every prepregnancy BMI category (adjusted risk ratio 1.16 to 1.33), and inadequate gain also in normal weight (1.13) and overweight (1.19). The lowest risk was at about 0.4 kg per week for underweight through overweight and about 0.1 kg per week in class III obesity.
Why it matters: it is observational, the source of prepregnancy weight is not always known (the authors note it may have been partly self-reported), and the data come from a single province, but its size reveals a dose-response curve useful for counseling; notably, 52.8% of pregnant women had excessive gain.
Sources
- [Article] Khademioore S, Darling EK, D'Souza R, et al. «Weight Gain During Pregnancy and Severe Maternal Morbidity». JAMA Netw Open. 2026;9(10):e2640027. DOI: 10.1001/jamanetworkopen.2026.40027. Open access (CC BY-NC-ND). https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2855699
3. ACOG practice advisory on GLP-1 receptor agonists in pregnancy and lactation
[Guideline] [United States]
Published October 2026 (ACOG news release dated October 23). ACOG recommends counseling that safety data in pregnancy are lacking, considering discontinuation 1 to 2 months before conception, discussing reliable contraception for those not seeking pregnancy (weight loss may increase fertility), advising against use during pregnancy, and, in lactation, shared decision-making: if used, choose agents with shorter half-lives, monitor infant weight gain with the infant's clinician, and avoid use in mothers of preterm infants or neonates. Separately from the ACOG advisory, the FDA prescribing information for tirzepatide (Mounjaro, revised August 2026, sections 7.2 and 8.3) states that it may reduce the efficacy of oral hormonal contraceptives because of delayed gastric emptying and advises switching to a non-oral method or adding a barrier method for 4 weeks after initiation and after each dose escalation.
Why it matters: fetal safety data are insufficient and the document acknowledges it; its value lies in structuring counseling amid growing use of these drugs.
Sources
- [Official release] ACOG, Practice Advisory «Use of Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy and Lactation», October 2026. https://www.acog.org/clinical/guidance/practice-advisory/2026/10/use-of-glucagon-like-peptide-1-receptor-agonists-in-pregnancy-and-lactation/
- [Official release] ACOG, news release, October 23, 2026. https://www.acog.org/news/2026/10/acog-releases-new-guidance-on-use-of-glp-1s-in-pregnancy-lactation/
- [Regulator] FDA, Mounjaro (tirzepatide) prescribing information, revised August 2026, sections 7.2 and 8.3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s044s045lbl.pdf
- [Coverage] Healio, October 23, 2026. https://www.healio.com/news/womens-health-ob-gyn/20261023/acog-issues-longawaited-guidance-on-glp1s-during-pregnancy-lactation
- [Coverage] The OBG Project, October 24, 2026. https://www.obgproject.com/2026/10/24/glp-1-receptor-agonists-in-pregnancy-counseling-management-and-lactation-considerations/
Gynecologic oncology
4. TroFuse-005: sacituzumab tirumotecan improves overall survival in previously treated endometrial cancer
[Congress] [International; Merck and Kelun-Biotech]
Open-label phase 3 trial (ENGOT-en23/GOG-3095; NCT06132958) presented on October 26, 2026, in a Presidential Symposium at ESMO 2026 (Madrid, October 23-27; LBA11) and published simultaneously online in The Lancet. 776 patients with advanced or recurrent endometrial cancer after platinum and anti-PD-1/PD-L1 therapy (about 84% mismatch repair-proficient in each arm) were randomized (386 versus 390) to sacituzumab tirumotecan 4 mg/kg every 2 weeks or physician's choice chemotherapy (doxorubicin or paclitaxel). Median overall survival 19.0 versus 12.1 months (HR 0.68; 95% CI, 0.55-0.84), progression-free survival 7.2 versus 3.9 months (HR 0.59; 95% CI, 0.50-0.70), and objective response 35.1% versus 17.3%. In the safety population (384 versus 367 patients), treatment-related grade 3 or higher adverse events occurred in 54.4% versus 41.4%; treatment-related stomatitis of any grade 54.9% versus 14.4% (grade 3: 9.9% versus 1.6%); treatment-related anemia 62.5% versus 39.8%, and dry eye 18.5% versus 3.0%; after adjustment for exposure, only oral mucositis or stomatitis and ocular surface events remained more frequent with sacituzumab tirumotecan.
Why it matters: according to Merck, it is the first antibody-drug conjugate to show a statistically significant improvement in both overall and progression-free survival versus chemotherapy in this population; the open-label, industry-funded trial was published simultaneously in The Lancet, and the overall survival analysis was the first interim analysis.
Sources
- [Article] Lorusso D, et al. «Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial». Lancet. 2026. DOI: 10.1016/S0140-6736(26)02099-4. https://pubmed.ncbi.nlm.nih.gov/42933460/
- [Registry] NCT06132958, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06132958
- [Official release] Merck, October 26, 2026. https://www.merck.com/news/sacituzumab-tirumotecan-sac-tmt-reduced-the-risk-of-death-by-32-and-the-risk-of-disease-progression-or-death-by-41-compared-to-chemotherapy-in-certain-patients-with-advanced-or-recurrent-endometrial/
- [Coverage] TargetedOnc, ESMO 2026 Presidential Symposium III. https://www.targetedonc.com/view/esmo-2026-presidential-symposium-iii-artemis-011-trofuse-005-keynote-c93-moio
- [Coverage] OncoDaily. https://oncodaily.com/oncolibrary/trofuse-005
- [Coverage] OncLive, October 26, 2026. https://www.onclive.com/view/sac-tmt-improves-pfs-and-os-is-under-fda-priority-review-in-previously-treated-endometrial-cancer
- [Coverage] CancerNetwork, October 26, 2026. https://www.cancernetwork.com/view/sac-tmt-improves-survival-vs-chemotherapy-in-pretreated-endometrial-cancer
- [Coverage] 2 Minute Medicine, October 29, 2026. https://www.2minutemedicine.com/sacituzumab-tirumotecan-improved-progression-free-and-overall-survival-versus-chemotherapy-in-previously-treated-endometrial-cancer/
5. KEYNOTE-C93: pembrolizumab alone versus chemotherapy as first-line therapy for dMMR endometrial cancer
[Congress] [International; Merck]
Multicenter, open-label, active-comparator phase 3 trial funded by Merck (GOG-3064/ENGOT-en15; NCT05173987), presented on October 26, 2026, in a Presidential Symposium at ESMO 2026 (LBA12) and published online the same day in The Lancet as an interim analysis. 299 patients (149 versus 150) with mismatch repair-deficient advanced or recurrent endometrial cancer and no prior systemic therapy for advanced disease (prior adjuvant or neoadjuvant chemotherapy was allowed if recurrence occurred at least 6 months after the last dose) were randomized to pembrolizumab 400 mg every 6 weeks (up to 18 cycles) or carboplatin-paclitaxel. Median progression-free survival 38.2 versus 8.4 months (HR 0.57; 95% CI, 0.42-0.79); overall survival HR 0.77 (95% CI, 0.52-1.15), not significant, with 70.7% versus 62.0% alive at 36 months; similar objective response (64.1% versus 62.1%); grade 3 or higher treatment-related adverse events 18.1% versus 50.7%.
Why it matters: pembrolizumab alone prolonged progression-free survival versus carboplatin-paclitaxel, but the trial did not compare monotherapy with chemotherapy plus immunotherapy; the progression-free survival curves crossed at about 6 months, and permitted crossover (85.2% of chemotherapy-arm patients who progressed received subsequent immunotherapy) dilutes the overall survival reading; for centers without regular access to immunotherapy, the data underscore the need to determine MMR status routinely.
Sources
- [Article] Slomovitz BM, et al. «First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial». Lancet. 2026. DOI: 10.1016/S0140-6736(26)02095-7. https://pubmed.ncbi.nlm.nih.gov/42933458/
- [Registry] NCT05173987, ClinicalTrials.gov.
- [Official release] Merck, October 26, 2026. https://www.merck.com/news/keytruda-pembrolizumab-as-monotherapy-reduced-the-risk-of-disease-progression-or-death-by-43-for-certain-patients-with-advanced-or-recurrent-endometrial-cancer-with-mismatch-repair-deficient/
- [Coverage] TargetedOnc, ESMO 2026 Presidential Symposium III. https://www.targetedonc.com/view/esmo-2026-presidential-symposium-iii-artemis-011-trofuse-005-keynote-c93-moio
- [Coverage] OncLive, October 26, 2026. https://www.onclive.com/view/keynote-c93-shows-pfs-benefit-with-first-line-pembrolizumab-in-dmmr-endometrial-cancer
- [Coverage] The ASCO Post, November 4, 2026. https://ascopost.com/news/november-2026/first-line-pembrolizumab-improves-progression-free-survival-in-dmmr-advanced-endometrial-cancer/
6. DUO-E: durvalumab plus olaparib, interim overall survival in advanced endometrial cancer
[Congress] [International; AstraZeneca]
Interim overall survival analysis (52% maturity) of the DUO-E trial (phase 3, double-blind, placebo-controlled; GOG-3041/ENGOT-EN10; NCT04269200; 718 patients with newly diagnosed stage III/IV or recurrent disease, randomized 1:1:1) presented on October 24, 2026, at ESMO 2026 (LBA37). Carboplatin-paclitaxel plus durvalumab followed by durvalumab plus olaparib maintenance reached a median of 51.1 months versus 39.6 months with carboplatin-paclitaxel followed by placebo (HR 0.77; 95% CI, 0.60-0.98; nominal P = .037, not meeting the prespecified threshold); with durvalumab without olaparib, 40.7 months (HR 0.87; 95% CI, 0.68-1.11; not significant). In the exploratory dMMR subgroup, the overall survival hazard ratio for the combination versus the control arm was 0.43 (95% CI, 0.21-0.83). In pMMR it was 0.85 (95% CI, 0.65-1.11; medians of 45.8 versus 37.8 months). These estimates do not establish a difference in effect by mismatch repair status.
Why it matters: the 11.5-month gain is not statistically conclusive and the final analysis is pending; the effect in pMMR, the larger group, remains uncertain.
Sources
- [Registry] NCT04269200, ClinicalTrials.gov.
- [Official release] AstraZeneca, October 19, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-present-survival-data-from-four-pivotal-phase-iii-trials-at-esmo-2026-featuring-sone-ve-imfinzi-tagrisso-orpathys.html
- [Official release] MD Anderson Cancer Center, October 24, 2026 (institution of the principal investigator, Shannon Westin; 718 patients, abstract LBA37). https://www.mdanderson.org/newsroom/research-newsroom/esmo-2026--immunotherapy-combination-extends-survival-in-advanced-endometrial-cancer.h00-159859290.html
- [Coverage] OncoDaily, October 24, 2026. https://oncodaily.com/oncolibrary/duo-e
- [Coverage] OncLive, October 24, 2026. https://www.onclive.com/view/durvalumab-plus-olaparib-improves-os-in-advanced-endometrial-cancer
7. VGX-3100 (DNA immunotherapy) for HPV-16/18-associated high-grade cervical lesions: positive Chinese phase 3
[Clinical trial] [China]
The HPV-303CHN trial (ChiCTR2300071848), randomized 2:1, double-blind, placebo-controlled at 22 sites in China, presented at the SITC 2026 Annual Meeting (Phoenix, November 4-8; abstract 1184). Participants received VGX-3100 6 mg intramuscularly with electroporation or placebo on day 1 and at weeks 4 and 12. The primary modified intention-to-treat analysis (patients who completed all 3 doses and had at least one efficacy assessment) included 207 women with CIN2/3 and HPV-16, HPV-18, or both (139 with VGX-3100 and 68 with placebo). At week 36, the composite of histologic regression plus HPV-16/18 clearance was achieved in 52.5% versus 35.3% (difference 17.2 percentage points; 95% CI 2.7 to 30.6 percentage points; P = .025). Serious adverse events 3.6% versus 2.9%, none treatment related; in one patient in the active arm, invasive squamous cell carcinoma was found at week 36, judged unrelated.
Why it matters: the product belongs to Inovio, and ApolloBio is its partner in China; on May 21, 2026, Inovio released, without figures, the topline results announced by ApolloBio (primary endpoint met); the figures come from the SITC presentation in November by an Inovio executive, as reported by OncLive; the absolute difference is modest and follow-up continues through week 88. Conization remains the standard, but a nonsurgical option would appeal to young women wishing to preserve fertility.
Sources
- [Meeting] Lyu N, Wang W, Zhao J, et al. «VGX-3100 DNA immunotherapy for HPV-16/18–associated cervical high-grade squamous intraepithelial lesions: a randomized, double-blind, placebo-controlled phase III trial (HPV-303CHN)». SITC 2026 Annual Meeting, Phoenix, November 4-8, 2026. Abstract 1184.
- [Registry] ChiCTR2300071848, ChiCTR.
- [Official release] Inovio, May 21, 2026. https://ir.inovio.com/news/news-details/2026/Positive-Topline-Results-from-a-Phase-3-Trial-for-VGX-3100-in-Cervical-Dysplasia-Patients-Announced-by-ApolloBio-INOVIOs-Partner-in-China/default.aspx
- [Coverage] OncLive, November 6, 2026. https://www.onclive.com/view/vgx-3100-elicits-regression-and-clearance-in-hpv-16-18-associated-cervical-hsils
- [Coverage] MyChesCo, May 31, 2026. https://www.mychesco.com/a/news/regional/inovio-partner-reports-phase-3-success-for-hpv-therapy-in-china/
Reproduction and gynecologic endocrinology
8. ACOG Clinical Practice Guideline No. 13: management of menopause-related vasomotor, sleep, and mood symptoms
[Guideline] [United States]
Published online October 15, 2026, in Obstetrics & Gynecology (2026;148(5):e345-e369); it replaces Practice Bulletin No. 141 (2014). Strong recommendation for systemic hormone therapy for vasomotor symptoms and associated sleep disturbance in patients without contraindications, initiated before age 60 or within 10 years of menopause; strong recommendation for the neurokinin receptor antagonists fezolinetant and elinzanetant (with liver function monitoring) and for SSRIs/SNRIs when hormones cannot or will not be used; conditional recommendations for conjugated estrogens-bazedoxifene, cognitive behavioral therapy, exercise, clinical hypnosis, and acupuncture; the evidence does not support phytoestrogens or herbal supplements, and for depressive symptoms the evidence is insufficient to recommend for or against hormone therapy.
Why it matters: it provides a clear framework for nonhormonal alternatives, although several recommendations (clinical hypnosis, acupuncture) are conditional and based on low-quality evidence. Regulatory context: the FDA requested labeling changes on November 10, 2025, and on February 12, 2026, approved the first changes for six products, removing references to cardiovascular disease, breast cancer, and probable dementia from the boxed warning; the boxed warning on endometrial cancer remains for systemic estrogen-alone products.
Sources
- [Article] American College of Obstetricians and Gynecologists. «ACOG Clinical Practice Guideline: Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms». Obstet Gynecol. 2026;148(5):e345-e369. DOI: 10.1097/AOG.0000000000006428. https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000006428~acog-clinical-practice-guideline-management-of
- [Official release] ACOG, Clinical Practice Guideline No. 13. https://www.acog.org/clinical/guidance/clinical-practice-guideline/2026/11/management-of-menopause-related-vasomotor-sleep-and-mood-symptoms/
- [Coverage] Contemporary OB/GYN, October 15, 2026. https://www.contemporaryobgyn.net/view/acog-guideline-expands-menopause-vms-sleep-and-mood-recommendations
- [Regulator] FDA, request for labeling changes for menopausal hormone therapies, November 10, 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-requests-labeling-changes-related-safety-information-clarify-benefitrisk-considerations
- [Regulator] FDA, approval of labeling changes for menopausal hormone therapy products, February 12, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
9. Contemporary hormone therapy and 12-year cardiovascular risk in Israel
[Congress] [Israel]
Retrospective matched cohort with a target-trial framework (Clalit Health Services) presented at the American Heart Association Scientific Sessions 2026 (Chicago, November 6-9; abstract MDP0654; news release dated November 2). 52,330 women aged 45 to 59 without atherosclerotic cardiovascular disease, venous thromboembolism, or cancer, half of them hormone therapy initiators (oral, transdermal, or gel), followed for a mean of 12 years. According to the presentation as reported by Healio, venous thromboembolism adjusted HR 1.01 (95% CI, 0.82-1.24); atherosclerotic cardiovascular disease 0.98 (0.93-1.04); death before age 80 1.03 (0.92-1.15); composite 1.00 (0.96-1.06). According to the AHA news release, results were similar across all formulations and routes of administration.
Why it matters: it is a non-peer-reviewed congress abstract, with exposure classified by first formulation only and risk of residual confounding, but its size and follow-up make it reassuring about early initiation; it does not apply to women with prior cardiovascular disease, thrombosis, or cancer, or to late initiation.
Sources
- [Official release] American Heart Association, November 2, 2026. https://newsroom.heart.org/news/long-term-study-finds-modern-hormone-replacement-therapy-not-linked-to-heart-disease-risk
- [Coverage] Healio, November 6, 2026. https://www.healio.com/news/cardiology/20261105/contemporary-hormone-therapy-does-not-worsen-cardiovascular-risk
10. Testosterone in postmenopausal women and cardiovascular risk: an observational signal from a US database
[Congress] [United States]
Retrospective propensity-matched cohort (TriNetX network; women aged 45 or older; mean follow-up of nearly 3 years) presented at The Menopause Society annual meeting (San Diego, October 20-24, 2026; news release dated October 20). 3,164 women on testosterone therapy versus 3,164 controls: incident composite cardiovascular disease 3.8% versus 0.5% (HR 8.08; 95% CI, 4.72-13.82); in the sensitivity analysis with baseline hormone therapy in both groups, 3.2% versus 0.5% (HR 6.73; 95% CI, 5-9.05).
Why it matters: dose, indication, and hormone levels are unknown, absolute rates are low, and an independent commentator questioned the comparability of the control group; the authors themselves call it hypothesis-generating, but it demands caution with off-label testosterone use.
Sources
- [Meeting] Jiang XD, et al. «Testosterone Therapy and Cardiovascular Risk in Postmenopausal Women: A Retrospective Propensity-Matched Cohort Study». The Menopause Society Annual Meeting 2026, San Diego, October 20-24, 2026.
- [Official release] The Menopause Society, October 20, 2026. https://menopause.org/press-releases/testosterone-therapy-may-increase-risk-of-cardiovascular-disease-in-postmenopausal-women
- [Coverage] Healio, November 2, 2026. https://www.healio.com/news/womens-health-ob-gyn/20261102/for-postmenopausal-women-testosterone-therapy-could-be-linked-to-higher-cvd-risk
Minimally invasive surgery and pelvic floor
No items selected for this issue.
Recent meetings
Calendar note after the close of the ten items: the AAGL congress (55th Global Congress on Minimally Invasive Gynecologic Surgery) took place November 13-16, 2026, in Boston, at the Hynes Convention Center. Official program: https://aagl.swoogo.com/aagl2026
Ready-to-paste WhatsApp text
*Obstetrics and Gynecology Bulletin — November 2026* Greetings, colleagues. Summary of what was verified between October 15 and November 12. 🤰 Obstetrics *Early metformin in gestational diabetes (EMERGE)* Secondary analysis, 526 pregnancies: less insulin initiation (win ratio 1.68), with no change in the original primary outcome. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2856230 *Gestational weight gain and severe maternal morbidity (Ontario)* 1,035,927 pregnancies: excessive gain was associated with more severe morbidity across every BMI category (risk ratio 1.16 to 1.33). https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2855699 *ACOG: GLP-1 receptor agonists in pregnancy and lactation* Consider stopping 1 to 2 months before conception, do not use in pregnancy, shared decision-making in lactation. https://www.acog.org/clinical/guidance/practice-advisory/2026/10/use-of-glucagon-like-peptide-1-receptor-agonists-in-pregnancy-and-lactation/ 🎗️ Oncology *TroFuse-005: sacituzumab tirumotecan in previously treated endometrial cancer* 776 patients; overall survival 19.0 vs 12.1 months (HR 0.68). More stomatitis, anemia, and ocular toxicity. https://www.merck.com/news/sacituzumab-tirumotecan-sac-tmt-reduced-the-risk-of-death-by-32-and-the-risk-of-disease-progression-or-death-by-41-compared-to-chemotherapy-in-certain-patients-with-advanced-or-recurrent-endometrial/ *KEYNOTE-C93: pembrolizumab alone in dMMR endometrial cancer* 299 patients; progression-free survival 38.2 vs 8.4 months versus carboplatin-paclitaxel (HR 0.57); overall survival not significant. It was not compared with chemotherapy plus immunotherapy. https://www.merck.com/news/keytruda-pembrolizumab-as-monotherapy-reduced-the-risk-of-disease-progression-or-death-by-43-for-certain-patients-with-advanced-or-recurrent-endometrial-cancer-with-mismatch-repair-deficient/ *DUO-E: durvalumab plus olaparib* Interim overall survival 51.1 vs 39.6 months (HR 0.77), not meeting the prespecified significance threshold. https://oncodaily.com/oncolibrary/duo-e *VGX-3100 in HPV-16/18 high-grade lesions (China)* Phase 3, modified intention-to-treat analysis, 207 women with HPV-16, HPV-18, or both: regression plus viral clearance 52.5% vs 35.3% with placebo (difference of 17.2 percentage points). https://www.onclive.com/view/vgx-3100-elicits-regression-and-clearance-in-hpv-16-18-associated-cervical-hsils 🧬 Reproduction and endocrinology *ACOG: new guideline on menopausal vasomotor, sleep, and mood symptoms* Hormone therapy with a strong recommendation; fezolinetant, elinzanetant, and SSRIs/SNRIs with a strong recommendation when hormones cannot or will not be used. https://www.acog.org/clinical/guidance/clinical-practice-guideline/2026/11/management-of-menopause-related-vasomotor-sleep-and-mood-symptoms/ *Modern hormone therapy and cardiovascular risk (Israel)* Cohort of 52,330 women, 12 years: no excess cardiovascular events, thrombosis, or death (HR 1.00 for the composite). https://www.healio.com/news/cardiology/20261105/contemporary-hormone-therapy-does-not-worsen-cardiovascular-risk *Testosterone in postmenopausal women (TriNetX)* 3,164 vs 3,164 women: cardiovascular disease 3.8% vs 0.5% (HR 8.08); an observational signal that needs confirmation. https://www.healio.com/news/womens-health-ob-gyn/20261102/for-postmenopausal-women-testosterone-therapy-could-be-linked-to-higher-cvd-risk 🔬 Surgery and pelvic floor No items in this issue. 📅 Calendar note after the close: the AAGL congress took place November 13-16, 2026, in Boston. Full bulletin and audio: https://boletinesmedicos.com/en/obgyn/2026-11-12.html
Ready-to-paste LinkedIn post
Monthly obstetrics and gynecology bulletin — November 12, 2026 Ten items, each with its sources linked: JAMA Network Open, The Lancet, Obstetrics & Gynecology, ACOG, ESMO 2026, SITC 2026, The Menopause Society, and the American Heart Association. Three worth your time: • TroFuse-005 (ESMO): sacituzumab tirumotecan raised median overall survival from 12.1 to 19.0 months (HR 0.68) in previously treated endometrial cancer; open-label, industry-funded trial published in The Lancet, with frequent stomatitis, anemia, and ocular toxicity. • KEYNOTE-C93 (ESMO): pembrolizumab alone versus chemotherapy as first-line therapy for dMMR endometrial cancer, progression-free survival 38.2 versus 8.4 months (HR 0.57); overall survival was not significant, and the trial did not compare it with chemotherapy plus immunotherapy. • Contemporary hormone therapy (Israel, 52,330 women, 12 years): HR 1.00 for the composite of cardiovascular disease, thrombosis, and death; congress abstract, not yet peer-reviewed. Full bulletin, with a critical reading of each study and links to its sources: https://boletinesmedicos.com/en/obgyn/2026-11-12.html #ObGyn #Obstetrics #Gynecology #EndometrialCancer #Menopause
Ready-to-paste X (Twitter) post
ObGyn bulletin, Nov 2026: TroFuse-005 (ESMO) lifts median overall survival from 12.1 to 19.0 months in treated endometrial cancer (HR 0.68). KEYNOTE-C93: pembrolizumab alone, progression-free survival 38.2 vs 8.4 months in dMMR. https://boletinesmedicos.com/en/obgyn/2026-11-12.html
Get every issue by email
Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.